All results
3 results for randomized double blind placebo controlled study assess efficacy safety and
-
PVT-2201-301
This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
ATYR
This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK),…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
Efficacy and Safety of AMG 570 in Subjects With Active SLE
The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with SLE…
- Ages
- 18 Years - 75 Years
- Sexes
- All